VBI Vaccines has chosen to advance two candidates from its VBI-2900 COVID-19 vaccine program into an adaptive Phase I/II study set to start by year’s end. One is VBI-2901, a trivalent pan-coronavirus vaccine candidate designed to express the Spike proteins of SARS-CoV-2, as well as SARS-CoV-1 and MERS. The other, VBI-2902, is a monovalent vaccine expressing only the SARS-CoV-2 Spike protein . . .
